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Abstract
Background: Case management has been shown to be beneficial in phases of cancer screening and treatment.
After treatment is completed, patients experience a loss of support due to reduced contact with medical
professionals. Case management has the potential to offer continuity of care and ease re-entry to normal life. We
therefore aim to investigate the effect of case management on quality of life in early cancer survivors.
Methods: Between 06/2010 and 07/2012, we randomized 95 patients who had just completed cancer treatment in
11 cancer centres in the canton of Zurich, Switzerland. Patients in the case management group met with a case
manager at least three times over 12 months. Patient-reported outcomes were assessed after 3, 6 and 12 months
using the Functional Assessment of Cancer Therapy (FACT-G) scale, the Patient Assessment of Chronic Illness Care
(PACIC) and the Self-Efficacy scale.
Results: The change in FACT-G over 12 months was significantly greater in the case management group than in
the control group (16.2 (SE 2.0) vs. 9.2 (SE 1.5) points, P = 0.006). The PACIC score increased by 0.20 (SE 0.14) in the
case management group and decreased by 0.29 (SE 0.12) points in the control group (P = 0.009). Self-Efficacy
increased by 3.1 points (SE 0.9) in the case management group and by 0.7 (SE 0.8) points in the control group
(P = 0.049).
Conclusions: Case management has the potential to improve quality of life, to ease re-entry to normal life and to
address needs for continuity of care in early cancer survivors.
Trial registration: The study has been submitted to the ISRCTN register under the name “Case Management in
Oncology Rehabilitation” on the 12th of October 2010 and retrospectively registered under the number
ISRCTN41474586 on the 24th of November 2010.
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Background
Cancer and its associated multimodal therapies have long-
term negative effects on quality of life. Many survivors ex-
perience declines in physical, psychological, and social
functioning and perceived role function, which signifi-
cantly impacts their careers [1–4]. This risk of decline
strongly varies between patients and is greater in socially
isolated patients [5, 6]. Consequently, patients need
tailored support when they return to everyday life after
undergoing cancer treatment. With the trend of decentred
outpatient care, patients must meet with numerous differ-
ent healthcare providers. Therefore, despite the fact that
social counselling, psycho-oncological therapy and oppor-
tunities to increase physical fitness are widely offered, the
needs of patients frequently cannot be met [7, 8]. The rea-
sons are multifaceted: after undergoing treatment, many
patients struggle to identify their needs for re-entry into
everyday life, and they lack energy to organize their re-
habilitation measures, which are also uncoordinated [9].
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These challenges have many similarities with those en-
countered by patients with chronic medical conditions.
It therefore seems likely that the features of the chronic
care model could address many of the mentioned bur-
dens [10]. Our hypothesis was that case management
(CM) could be one way to address behavioural and psy-
chosocial issues better than usual care. A case manager
can assess patients’ needs; identify barriers; inform pa-
tients about existing rehabilitation programmes; ensure
coordination between the patient, physicians and other
care providers; and thus offer care for cancer survivor-
ship in accordance with the chronic care model [11].
Moreover, a case manager can aim at empowering pa-
tients in organizing targeted measures, thus promoting
self-management skills, self-efficacy and lifestyle modifi-
cations [12, 13]. These interventions may enable cancer
survivors to cope with the long-term consequences of
cancer and thus increase health-related quality of life
and may support employability.
CM or similar models of advanced nursing (such as
patient navigation, pivot nursing or contact nursing)
have been assessed for the phases of cancer screening
and cancer treatment, showing mixed results [14, 15].
Recent studies investigating patients during cancer treat-
ment showed a decrease in emergency room visits and
lower cancer-related medical costs [16, 17]. However, no
studies are available on the effects of CM on quality of
life after completion of cancer treatment. To assess this,
we aimed at comparing the effect of CM versus usual
care on the quality of life in early cancer survivors.
Methods
The rationale, design and methods of the study have been
reported previously [18]. The study protocol was approved
by the ethics committee of the canton of Zurich on the
10th of May 2010 (Ref. KEK-ZH-NR: 2009–0145/1).
Patient population
The inclusion criteria were 18 years old or older, com-
pletion of a curatively intended cancer treatment
(chemotherapy, radiotherapy and/or surgery), expected
survival of at least 1 year, increased distress scale (≥3)
according to the commonly used Distress Thermometer
[19], and need of and intention to undertake rehabilita-
tion according to patient’s perspective. Due to difficulties
in patient recruitment, two inclusion criteria had to be
altered from the protocol: patients with all types of can-
cer were eligible instead of patients with breast cancer
only, and the initially required Distress Thermometer
between 3 and 7 was extended to an upper limit of 9.
Patients with a Distress Thermometer >7 (high distress)
were immediately contacted by the study nurse to assess
if further referral to psychiatric support was needed. Fol-
lowing this brief assessment, only patients reporting a
temporary and not persistent severe distress were in-
cluded in the study. The exclusion criteria were treatment
completed more than 1 month ago, metastasis and/or ad-
vanced stage disease, cancer relapse during study, pallia-
tive treatment, insufficient knowledge of German to
participate in counselling and evaluation, or severe psychi-
atric disease. Patients with a relapse (3 in the CM group
and 2 in the usual care (UC) group) were excluded from
the intention-to-treat analysis, but CM was continued for
ethical reasons. Nurses and physicians in 11 cancer cen-
tres in the region of Zurich informed eligible patients
about the study and with their permission transmitted
contact data to the study nurse, who asked the patients
for written informed consent.
Randomization
The randomization of the list was performed by a scientist
at the Institute of Primary Care not involved in the study.
Patients were randomized with computer generated num-
bers, in block sizes of 2 and 4, stratified according to the
type of cancer. The study nurse attributed the next follow-
ing number to each patient and opened the sealed num-
bered envelope containing the randomization allocation.
Intervention
Details on the intervention concept have been reported in
the study protocol [18]. The five case managers were nurses
specializing in oncology, skilled in discussing patients’ prob-
lems in an empathic way and able to offer resource-
oriented, self-empowering motivational counselling. During
the first 3 months, they met with the patients at least three
times to establish a relationship, assess needs, and generate
an action plan. By means of a standardized structured elec-
tronic tool, the following items were addressed: past med-
ical history (in the first interview), current mental state,
stresses and challenges, influencing factors, resources, goals
and measures. The case managers provided information on
available services and therapies and helped organize ap-
pointments. In the following months, they performed tele-
phone follow-ups according to individual patients’ needs.
The case managers were available on demand during office
hours. The entire intervention lasted up to 12 months with
a final concluding interview.
Outcome measures
The study nurse sent out questionnaires to the patients
with a stamped response envelope at baseline, three, six
and 12 months. Non-responding patients were contacted
once by phone. The primary outcome was health-related
quality of life at 12 months. It was measured with the
Functional Assessment of Cancer Therapy-General
(FACT-G) questionnaire [20]. The FACT score rates the
health-related quality of life in patients treated for can-
cer. The score sums up to a total ranging from zero to
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108 points, where a higher score indicates better quality
of life. The secondary outcomes were Self-Efficacy mea-
sured with the Jerusalem & Schwarzer questionnaire
[21]. The result can range between 10 and 40 with a
higher score indicating more self-efficacy (meaning hav-
ing a stronger belief in one’s competence to cope with a
broad range of stressful or challenging demands). Ac-
cordance of received care with the chronic care model
was evaluated with the Patient Assessment of Chronic
Illness Care (PACIC) [22]. The PACIC Score can range
between one and five, with a higher score indicating a
better accordance of care with the chronic care model.
The PACIC was slightly adapted to be used in the con-
text of rehabilitation for cancer survivorship instead of
care for chronic illness. Patients were asked about their
employability and family status. Health utilization as well
as other support measures or services utilized in the last
3 months were assessed. Finally, patients were asked if
they made conscious changes in their lives with respect
to their physical activity, diet, work, and relaxation
practice.
Safety issues
As stated in the informed consent patient form, serious
risks or undesired effects of the intervention or the as-
sessment by questionnaires have not been described in
the literature. There are no specific risks related to the
study. The study is being conducted in accordance with
medical professional codex and the Helsinki Declaration
as of 1996 as well as Data Security Laws. Study partici-
pation of patients is voluntary and can be cancelled at
any time without provision of reasons and without nega-
tive consequences for their future medical care.
Statistical analysis
All analyses were performed according to the intention-
to-treat principle and therefore used the latest available
measurement for missing values (last observation carried
forward). The sum of the FACT-G items was calculated
allowing three missing items per domains and five of the
overall items (out of 27). The average value for the
PACIC and Self-Efficacy items was calculated. Three
missing items (out of 20) were allowed for the construc-
tion of the PACIC and three (out of 10) for the construc-
tion of the Self-Efficacy questionnaire. Residual missing
values were replaced by the mean of the remaining values.
For the other outcomes, the missing values are mentioned
in the result tables. Continuous outcomes were compared
with the Wilcoxon Rank-Sum and with the unpaired t-
test. Categorical variables were compared with the Fisher’s
exact and chi-square test. Changes in proportions over
time were compared with the McNemar test and change
of continuous variable with the paired t-test. To account
for differences in baseline FACT-G, PACIC and Self-
Efficacy, a linear regression analysis of the 12 month
values adjusted for baseline as well as for Distress Therm-
ometer was performed. Adjusted means for each group
and adjusted differences in change in and between groups
were computed. The effect size was computed by dividing
the adjusted difference in change by the pooled baseline
standard deviation. To assess the trend of the time course
and of the intervention on outcomes within groups and
between groups, a mixed effect linear regression for re-
peated measures was performed including an interaction
term (time*group) as a covariate. We controlled for a
potential cluster effect of treatment centre and coa-
ches on the primary outcome by comparing the re-
gression model with a hierarchical model clustered
for cancer treatment centre and coaches using the
likelihood-ratio test. All of the reported P values were
2-sided. A P < 0.05 was considered statistically signifi-
cant. All of the analyses were performed with Stata-
Corp. 2013. Stata Statistical Software: Release 13.
College Station, TX, USA: StataCorp LP.
Patients assessed for eligibility (N=241)
Excluded
Distress Score >9
Declined to participate
Randomized (n=104) 
Allocated to case management
Received allocated intervention
Did not received allocated intervention:
(Withdrawn consent before baseline)
Allocated to standard care
Received allocated intervention
Did not received allocated intervention:
(Withdrawn consent before baseline)
Lost to 12-Months follow-up Lost to 12-Months follow up
Included in the intention-to-treat analysis
Excluded from analysis because of relapse
Included in the intention-to-treat analysis
Excluded from analysis because of relapse
(n=51)
(n=50)
(n=1)
(n=53)
(n=50)
(n=3)
(n=6)
(n=48)
(n=2)
(n=2)
(n=47)
(n=3)
(n=137)
(n=1)
(n=136) 
Fig. 1 CONSORT Flow-Chart
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Results
Of the 104 patients who agreed to participate, 51 were
allocated to CM and 53 to UC. One patient in the CM
group and three in the UC group withdrew consent be-
fore completing the baseline questionnaires and thus
could not be included in the analysis. Because of
organizational and financial reasons and difficulties with
recruiting, we could not further increase our sample
after these withdrawals. We excluded three patients in
the CM and two in the UC group from the analysis be-
cause of cancer recurrence. Ultimately, 47 patients in
the CM and 48 in the UC group were included in the
analysis. Two patients in the CM and three in the UC
group were lost to follow-up at 3 months, one more in
the UC group at 6 months and three more at 12 months
(Fig. 1). These patients declined to complete further
questionnaires or moved without giving their new
address and phone number to the study nurse (but did
not withdraw consent).
The baseline characteristics of the study population
are presented in Table 1. Overall, 92% of the patients
were female, and the mean age was 50 years. The FACT-
G was significantly different between the groups at base-
line, with a mean (SD) of 67.9 (16.0) points in the CM
and 74.9 (14.3) in the UC group (P = 0.03). The Distress
Thermometer was significantly higher in the CM than in
the UC group (6.2 (SD 1.46) vs. 5.6 (SD 1.45) P = 0.04).
Primary outcome
In comparison to baseline, both groups had a significant in-
crease of FACT-G over 12 months (both P < 0.001) (Fig. 2).
There was no difference in FACT-G between the groups at
12 months. The increase in the CM group was significantly
greater than the increase in the UC group (mean (SE) 16.2
(2.0) versus 9.2 (1.5) points (P = 0.006), with a mean di-
fference in change between groups of 7.0 (2.5) points
(P = 0.006). The increase in the FACT-G after 12 months
in the CM compared to the UC group remained signifi-
cantly higher when adjusted for differences in baseline
Table 1 Baseline Characteristics
CM
n = 47
UC
n = 48
No. (%) No. (%) P
Female 41 (87) 46 (96) .16
Family Status .77
Single 12 (26) 12 (25)
Married 21 (45) 26 (54)
Widowed 1 (2) 1 (2)
Divorced/Separated 13 (28) 9 (19)
Foreigner 12 (26) 11 (23) .81
Cancer localization 1
Breast 35 (75) 35 73
Colorectal 4 (9) 5 (10)
Lungs 1 (2) 0
Hodgkin lymphoma 1 (2) 0
Uveal Melanoma 0 1 (2)
Non-Hodgkin lymphoma 2 (4) 3 (6)
Ovarian 2 (4) 3 (6)
Prostate 1 (2) 0
Cervix 0 1 (2)
Larynx 1 (2) 0
Cancer therapy
Chemotherapy 45 (96) 44 (92) .68
Radiotherapy 39 (83) 36 (75) .45
Hormonal therapy 24 (51) 28 (58) .54
Surgery 43 (91) 44 (92) 1
Age, Mean 49.6 50.8 .56
SD 11.0 8.9
School years, Mean 14.8 13.8 .17
SD 4.1 3.3
Patient-reported Outcomes
FACT-G, Mean 67.9 74.9 .03
SD 16.0 14.3
Self-Efficacy, Mean 26.8 28.2 .19
SD 4.9 5.5
PACIC, Meana 2.33 2.61 .13
SD 0.80 0.97
Distress Thermometer, Meanb 6.2 5.6 .04
SD 1.46 1.45
CM case management, UC usual care, SD standard deviation, FACT-G functional
assessment of cancer therapy, ICR interquartile range, PACIC patient
assessment of chronic illness care
a3 missing in CM, 1 missing in UC
b1 missing in CM, 1 missing in UC
65
70
75
80
85
F
A
C
T
 S
ca
le
0 5 10 12
Months
Case Managment Usual Care
Standard Error
Fig. 2 Crude FACT-G scale mean over time. The repeated measure
mixed model regression analysis showed a significant trend for time
overall (P < 0.001) and a significant trend for time* group (P = 0.002)
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FACT-G and Distress Thermometer (Table 2). The effect
size (Cohen d) was moderate, with a value of 0.43. The
cluster analysis showed no cluster effect for the cancer
treatment centre or for the coach on the FACT-G
(P < 0.0001).
Secondary outcomes
Self-Efficacy increased in the CM group (29.9 (SE 0.7)
vs. 26.8 (SE 0.7), P = 0.001) and showed no significant
change over time in the UC group (28.9 (SE 0.9) vs. 28.2
(SE 0.8), P = 0.38) (Fig. 3). Thus, the change was sig-
nificantly higher in the CM than in the UC group (3.1
(SE 0.9) versus 0.7 (SE 0.8) points, P = 0.049).
The PACIC score decreased continuously over the
12 months in the UC group from 2.61 (SE 0.14) to 2.32
(SE 0.13) points (P = 0.02) (Fig. 4). In the CM group,
PACIC initially increased over 3 months (2.32 (SE 0.11)
vs. 2.71 (SE 0.10), (P = 0.0003) and then tended to de-
crease again over the remaining time ((2.56 (SE 0.12) vs.
2.75 (SE 0.11), P = 0.06). There were no differences be-
tween the groups in the self-reported changes in diet,
physical activity, relaxation practice (see Additional file
1: Table S1) or in employability (Table 3).
There were no differences between the groups in the
amount of contact with a physician or the number of med-
ical and unplanned visits (see Additional file 2: Table S2).
Similarly, there were no differences in hospital or rehab-
ilitation clinic stay and median length of stay. Significantly
more patients in the UC group mentioned having met a
physiotherapist at 3 months (20 out of 45 versus 10 out of
46 in the CM group, P = 0.04) and a lymphatic drainage
therapist at 6 months (15 out of 46 vs. 5 out of 45 in the
CM group, P = 0.02). Significantly more patients in the CM
group mentioned having had support for childcare at 6 and
12 months (7 out of 45 in the CM group versus none in the
UC group, P = 0.012). There were no differences between
the use of other therapies (diet counselling, psychologist,
medical training therapy, stress reduction therapy, courses
to support quality of life, self-help groups, breast care nurse,
stoma care nurse, other nurse), services (national cancer
association, patient counselling office, social services, hu-
man resources, internet) or support (help for housekeeping,
for childcare, for personal hygiene) (see Additional file 3:
Table S3). Less than 10% of the patients used opiates, sleep-
ing pills, sedative analgesics or benzodiazepines, with no
difference between the groups at any point in time. Be-
tween 14 and 27% of all patients used antidepressant drugs,
without a significant difference between the groups at any
point in time (see Additional file 4: Table S4).
In both groups, the number of patients working full
time decreased significantly over 12 months (CM 14 to 6,
P = 0.039, UC 18 to 5, P < 0.001) with a significant
increase of patients working part time in the UC group
(20 to 27, P = 0.006) but not in the CM group (19 to 20,
P = 0.55) (Table 3). The number of patients with sick day
leaves decreased significantly in both groups (CM 32 to
13, P < 0.001, UC 34 to 9, P < 0.001), with no difference
between the groups at any point in time.
Discussion
Our study on CM among early cancer survivors showed
that, compared to UC, CM leads to a greater increase in
quality of life (FACT-G), higher Self-Efficacy scores, and
health care that is more in accordance with the chronic
care model (PACIC).
Although our study was not able to show a significant
absolute difference between the groups in the FACT-G
after 12 months, we still consider our main outcome as
highly relevant for two reasons: 1) the difference in
change in quality of life, adjusted for relevantly lower
FACT-G scores at baseline and other differences in
baseline characteristics, was not only highly significant
Table 2 Crude and Adjusted 12 Month Outcomes, Changes within and between Groups
12 Months Change within group Difference in Change
CM
n = 47
UC
n = 48
CM
N = 47
UC
n = 48
Mean SE Mean SE Mean SE Mean SE Mean SE P
FACT-G crude 82.0 2.2 81.6 2.2 16.2 2.0 9.2 1.5 7.0 2.5 .006
FACT-G adjusted for Baseline 84.3 1.7 79.3 1.6 15.2 1.7 10.2 1.7 5.0 2.4 .04
FACT-G adjusted for Baseline + Distress 84.8 1.7 78.8 1.6 15.7 1.7 9.7 1.6 6.0 2.4 .01
Self-Efficacy crude 29.9 0.7 28.9 0.9 3.1 0.9 0.7 0.8 2.4 1.2 .049
Self-Efficacy adjusted for Baseline 30.2 0.7 28.6 0.7 2.7 0.7 1.1 0.7 1.6 1.0 .13
Self-Efficacy adjusted for Baseline + Distress 30.5 0.7 28.4 0.7 3.0 0.7 0.8 0.7 2.1 1.0 .046
PACIC crude 2.56 0.12 2.32 0.13 0.20 0.14 −0.29 0.12 0.49 0.18 .009
PACIC adjusted for Baseline 2.60 0.12 2.25 0.11 0.13 0.11 −0.22 0.11 0.34 0.16 .034
PACIC adjusted for Baseline + Distress 2.62 0.12 2.24 0.12 0.14 0.12 −0.24 0.12 0.37 0.17 .03
CM case management, UC usual care, SE standard error, FACT-G functional assessment of cancer therapy, PACIC patient assessment of chronic illness care
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but also 2) highly relevant: the CM group showed a
difference (increase) in the FACT-G score of 7 points.
This value is greater than the minimal difference co-
nsidered significant of three, for which the study was
powered [18, 23].
A former study performed among early cancer survi-
vors shared similarity with our intervention and showed
an effect on mood and cancer-related concerns but spe-
cifically targeted an underserved population [24]. A self-
selected trial of phone-based case management could
decrease cost, but quality of life was not assessed [17].
Overall, a meta-analysis showed psycho-oncologic inter-
ventions to be associated with a small-to-medium posi-
tive effect on quality of life [25]. However, to our
knowledge, our study is the first to examine the effect of
CM on the quality of life of early cancer survivors.
Several reasons can explain the beneficial effect of CM
in this setting. First, the case manager provided import-
ant information on long-term symptoms and on [26]
available services and therapies. This is in accordance
with previous data, showing that cancer patients would
value additional information on many topics, including
chronic symptoms, handling long-term treatment in
everyday life, financial issues and preparation for return-
ing to work [27, 28]. A former study showed that a pa-
tient’s reported quality of life correlated with the access
to helpful information. Second, in accordance with the
chronic care model, the case manager offered a continu-
ity of care when appointments for treatment ceased and
medical follow up visits were less frequent [11]. Thus, CM
provided a type of substitution for decreasing healthcare
support. This finding is reflected in our data by an increase
of the PACIC in the first 3 months in the CM group, op-
posed to the overall decrease of PACIC throughout the
12 months of follow up in the UC group (Fig. 4). Third, the
case manager offered support to cope with the psycho-
logical issues of the re-entry phase to normal life [9]. The
assessment helped patients realize that they were facing
new needs and challenges. The motivational counselling
empowered self-management and gave them tools to face
the upcoming challenges [12]. These approaches are
reflected in the greater increase of the Self-Efficacy scale in
the CM group. Alternatively, patients’ needs were more ori-
entated to information, continuity and support to cope with
new challenges. Because we observed almost no changes in
the self-reported use of supporting services, medical train-
ing therapy, physiotherapy and psychotherapy, it seems un-
likely that the effect of the CM would have been mediated
by an increased use of these offers. Furthermore, our study
showed no effect on self-reported physical activity, diet, re-
laxation practice or employability. This finding was not sur-
prising because the case manager’s intervention was not
focused on convincing patients to adhere to a fitness
programme or to return to work. The effects of CM on
quality of life and Self-Efficacy are therefore not explained
by increases in health care use but rather by the psychoedu-
cational intervention of CM, a finding that is consistent
with former studies showing that psychoeducational inter-
ventions have positive effects on cancer patients [25].
Our study has several potential limitations. The main
limitation is the difference in baseline FACT-G between
the groups. We cannot exclude that the greater increase
of FACT-G in the CM group reflects the natural history of
cancer patients with worse health-related quality of life.
Another possible limitation is the self-selection process of
the patients. Because 137 of 241 eligible patients declined
to participate, we cannot conclude that the CM approach
would have positive effects on all patients. It is possible
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Fig. 4 Crude PACIC scale mean over time. The repeated measure
mixed model regression analysis in the UC group showed a
negative trend for time (P = 0.005)
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Fig. 3 Crude Self-Efficacy mean over time. The repeated measure
mixed model regression analysis showed a significant trend for time
overall (P < 0.001) and for time*group (P = 0.002)
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that this effect only occurs in patients with some affinity
for CM. Several studies showed a large heterogeneity in
the quality of life of cancer survivors, resulting in com-
pletely different needs for the re-entry phase [29, 30].
Most mentioned that the reason for declining to partici-
pate in our study was a lack of need for additional support.
More research is needed to determine how to select
patients likely to benefit from such a service. Further-
more, a frequent limitation of CM interventions is that
the effect of the case manager’s own personality re-
mains unclear. This bias can be excluded in our study,
as we had five different case managers and could not
detect any cluster effects. This finding reflects the stan-
dardized approach of our intervention and suggests its
transferability to other settings. A notable strength of
our study is that CM, as practiced in our intervention,
constitutes a new practice in Switzerland. Therefore, we
were able to compare the effect of CM versus UC in
early cancer survivors, a setting in which it had never
been tested and which is not possible in other countries
where similar nurse-led follow-ups have previously
been implemented [15, 31].
Conclusion
CM, in which a trained nurse assesses needs, offers in-
formation, and provides empowering support, eases re-
entry to normal life and addresses needs for continuity
of care in early cancer survivors. This is a practical ap-
proach to coordinate existing rehabilitation programmes
in the fragmented oncological healthcare system and to
address the heterogenic needs of cancer survivors. More
research is needed to identify the patients who can bene-
fit most from such interventions.
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1
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.44 1
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0
0;3
.16 0
0;2
0
0;1
.67
CM case management, UC usual care, IQR interquartile range
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